close

Agreements

Date: 2011-01-04

Type of information: R&D agreement

Compound: drug targets

Company: Kinaxo Biotechnology (Germany) AstraZeneca (UK)

Therapeutic area: Cancer Oncology

Type agreement:

R&D

Action mechanism:

Disease:

Details:

Kinaxo Biotechnology has entered into a collaboration with AstraZeneca. The german company will apply its technology platform to support one of AstraZeneca’s oncology programs. Its high-end mass spectrometry-based technologies will be used to quantitatively analyze posttranslational protein modifications on a proteome-wide scale. These analysis aim to gain valuable insights into cellular functions of potential drug targets .

Financial terms:

Financial details of the agreement were not disclosed.

Latest news:

Is general: Yes